Key Takeaways
- • Goldman Sachs Private Equity has emerged as the frontrunner to acquire ChrysCapital's minority stake in GVK Biosciences, with deal negotiations in their final stages as of April 18, 2021.
- • ChrysCapital holds a 16.77 percent stake in GVK Biosciences as of March 2020, acquired in 2015 when it purchased Sequoia Capital's 10 percent position at an implicit valuation of $250 million for the company.
- • The transaction would mark Goldman Sachs' second domestic pure-play pharmaceutical investment, following its $150 million investment in Biocon Biologics in November 2020.
- • GVK Biosciences co-promoters (the GVK family and DS Brar, former Ranbaxy Labs CEO) may also sell partial stakes alongside ChrysCapital, potentially increasing the total stake offered and the overall transaction value.
- • The CRAM (contract research and manufacturing services) sector is commanding premium valuations globally, with recent precedent transactions including True North's acquisition of a stake in Anthem Biosciences and TPG's investment in Sai Lifesciences.
Summary
Goldman Sachs Private Equity has advanced to the final negotiation stage to acquire the minority stake held by ChrysCapital in GVK Biosciences, according to sources familiar with the matter. The transaction would represent a significant entry point for the Wall Street firm into India's contract research and manufacturing services (CRAM) sector, which has attracted substantial private equity attention due to rich valuations and strong global demand for outsourced pharmaceutical manufacturing capabilities.
ChrysCapital's stake in GVK Biosciences has appreciated considerably since the fund's initial entry in 2015, when it acquired a 10 percent position previously held by Sequoia Capital at an implicit company valuation of $250 million. By March 2020, ChrysCapital's position had grown to 16.77 percent, reflecting the company's value creation and the sector's favorable dynamics. The transaction builds on Goldman Sachs' established commitment to India's pharmaceutical sector, having invested $150 million in Biocon Biologics in November 2020, positioning this as the group's second major domestic pure-play pharma investment.
Beyond ChrysCapital's stake, additional shareholders have indicated willingness to participate in the transaction at appropriate valuations. The GVK family and DS Brar—the former CEO and managing director of Ranbaxy Labs who currently leads GVK Biosciences—collectively control approximately 41.01 percent of the company as of March 2020 and may sell partial stakes alongside ChrysCapital. This combined stake offering could enhance the overall value and control implications of the transaction for Goldman Sachs.
The CRAM sector has demonstrated robust valuations in both domestic and international markets, with several recent precedent transactions reinforcing sector strength. True North partnered with Anthem Biosciences while TPG invested in Sai Lifesciences, reflecting competitive interest among institutional investors in capturing exposure to India's growing outsourced pharmaceutical manufacturing capabilities. Goldman Sachs' advancement as the frontrunner against competing bidders underscores the deal's attractiveness and the firm's strategic focus on high-quality assets within India's life sciences ecosystem.
ChrysCapital's stake in GVK Biosciences has appreciated considerably since the fund's initial entry in 2015, when it acquired a 10 percent position previously held by Sequoia Capital at an implicit company valuation of $250 million. By March 2020, ChrysCapital's position had grown to 16.77 percent, reflecting the company's value creation and the sector's favorable dynamics. The transaction builds on Goldman Sachs' established commitment to India's pharmaceutical sector, having invested $150 million in Biocon Biologics in November 2020, positioning this as the group's second major domestic pure-play pharma investment.
Beyond ChrysCapital's stake, additional shareholders have indicated willingness to participate in the transaction at appropriate valuations. The GVK family and DS Brar—the former CEO and managing director of Ranbaxy Labs who currently leads GVK Biosciences—collectively control approximately 41.01 percent of the company as of March 2020 and may sell partial stakes alongside ChrysCapital. This combined stake offering could enhance the overall value and control implications of the transaction for Goldman Sachs.
The CRAM sector has demonstrated robust valuations in both domestic and international markets, with several recent precedent transactions reinforcing sector strength. True North partnered with Anthem Biosciences while TPG invested in Sai Lifesciences, reflecting competitive interest among institutional investors in capturing exposure to India's growing outsourced pharmaceutical manufacturing capabilities. Goldman Sachs' advancement as the frontrunner against competing bidders underscores the deal's attractiveness and the firm's strategic focus on high-quality assets within India's life sciences ecosystem.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.